Free Trial

CervoMed (CRVO) Competitors

CervoMed logo
$6.30 +0.43 (+7.33%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$6.36 +0.06 (+0.95%)
As of 08:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRVO vs. IMAB, CRDF, INBX, MDWD, SOPH, MNPR, SCPH, DSGN, VOR, and ACIU

Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include I-Mab (IMAB), Cardiff Oncology (CRDF), Inhibrx Biosciences (INBX), MediWound (MDWD), SOPHiA GENETICS (SOPH), Monopar Therapeutics (MNPR), scPharmaceuticals (SCPH), Design Therapeutics (DSGN), Vor Biopharma (VOR), and AC Immune (ACIU). These companies are all part of the "pharmaceutical products" industry.

CervoMed vs. Its Competitors

I-Mab (NASDAQ:IMAB) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

I-Mab presently has a consensus target price of $6.00, indicating a potential upside of 172.73%. CervoMed has a consensus target price of $22.57, indicating a potential upside of 258.28%. Given CervoMed's higher possible upside, analysts clearly believe CervoMed is more favorable than I-Mab.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
I-Mab
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33
CervoMed
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
2.89

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 22.1% of I-Mab shares are owned by insiders. Comparatively, 35.4% of CervoMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, I-Mab and I-Mab both had 2 articles in the media. CervoMed's average media sentiment score of 1.29 beat I-Mab's score of -0.09 indicating that CervoMed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
I-Mab
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CervoMed
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CervoMed has higher revenue and earnings than I-Mab.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
I-Mab$3.89M46.18-$22.23MN/AN/A
CervoMed$9.74M5.63-$16.29M-$2.18-2.89

I-Mab has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, CervoMed has a beta of -0.75, meaning that its stock price is 175% less volatile than the S&P 500.

I-Mab has a net margin of 0.00% compared to CervoMed's net margin of -200.57%. I-Mab's return on equity of -19.81% beat CervoMed's return on equity.

Company Net Margins Return on Equity Return on Assets
I-MabN/A -19.81% -18.63%
CervoMed -200.57%-44.07%-40.65%

Summary

I-Mab and CervoMed tied by winning 7 of the 14 factors compared between the two stocks.

Get CervoMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRVO vs. The Competition

MetricCervoMedMED IndustryMedical SectorNASDAQ Exchange
Market Cap$51.08M$2.87B$5.50B$8.95B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-2.8920.8026.9720.11
Price / Sales5.63286.31425.92119.81
Price / CashN/A41.1936.8257.86
Price / Book1.407.487.985.56
Net Income-$16.29M-$55.04M$3.16B$248.40M
7 Day Performance13.31%2.44%2.36%4.67%
1 Month Performance-18.60%1.90%2.15%6.64%
1 Year Performance-58.74%4.35%33.78%21.31%

CervoMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRVO
CervoMed
3.1853 of 5 stars
$6.30
+7.3%
$22.57
+258.3%
-59.2%$51.08M$9.74M-2.894News Coverage
Positive News
IMAB
I-Mab
2.728 of 5 stars
$2.42
-5.8%
$6.00
+147.9%
+41.0%$209.87M$3.89M0.00380Gap Up
CRDF
Cardiff Oncology
1.6864 of 5 stars
$3.15
flat
$9.88
+213.5%
+77.5%$209.56M$680K0.0020News Coverage
Analyst Forecast
INBX
Inhibrx Biosciences
0.9893 of 5 stars
$14.27
-1.1%
N/A+46.5%$208.89M$200K0.12166News Coverage
MDWD
MediWound
1.619 of 5 stars
$19.37
+0.6%
$31.80
+64.2%
+0.1%$208.16M$20.22M0.0080
SOPH
SOPHiA GENETICS
2.3499 of 5 stars
$3.10
+0.3%
$7.00
+125.8%
-21.2%$206.06M$65.17M0.00520News Coverage
Positive News
MNPR
Monopar Therapeutics
2.8969 of 5 stars
$35.78
+6.5%
$56.50
+57.9%
+940.0%$205.47MN/A0.0010News Coverage
Analyst Forecast
Gap Up
SCPH
scPharmaceuticals
4.1364 of 5 stars
$3.81
-1.6%
$14.00
+267.5%
-9.4%$204.30M$36.33M0.0030
DSGN
Design Therapeutics
0.3745 of 5 stars
$3.37
-5.6%
$4.00
+18.7%
+4.0%$202.66MN/A0.0040Positive News
VOR
Vor Biopharma
3.9425 of 5 stars
$1.62
+52.8%
$5.63
+247.4%
+164.9%$202.44MN/A-0.98140Options Volume
Gap Up
High Trading Volume
ACIU
AC Immune
2.7562 of 5 stars
$2.03
+1.0%
$12.00
+491.1%
-40.5%$201.82M$31.02M0.00140

Related Companies and Tools


This page (NASDAQ:CRVO) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners